Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: KA-P, SDT, AMD, AA, LB, TC and DWH have no conflicts of interest to declare. GG has received honoraria and meeting support from AbbVie Biotherapeutics, Biogen, Canbex, Ironwood, Novartis, Merck, Merck Serono, Roche, Sanofi Genzyme, Synthon, Teva and Vertex. He also serves as a chief editor for Multiple Sclerosis and Related Disorders. SG has received honoraria from Biogen Idec, Sanofi Genzyme, Janssen Cilag, Merck, Neurodiem, Novartis, Roche and Teva, and grant support from ECTRIMS, Genzyme, Merck, National MS Society, Takeda, UK MS Society, NIHR and NHSx. MM has received travel support and speaker honoraria from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva, and consultation for Celgene, Merck Serono, Novartis and Roche. JM has received honoraria and meeting support from Arvelle, Biogen, Novartis, Merck Serono, Roche, Sanofi Genzyme, Jazz Pharmaceuticals, Janssen and Novartis. BPT has received honoraria, travel grants, and has been a member of advisory boards for Biogen, Merck Serono, Novartis, Sanofi Genzyme and Roche. DB has received compensation from InMuneBio, Lundbeck, Merck, Novartis, Rock and Teva. KS has received research support, through Queen Mary University of London, from Biogen, Merck KGaA and Novartis, speaking honoraria from, and/or served in an advisory role for, Biogen, EMD Serono, Merck KGaA, Novartis, Roche, Sanofi-Genzyme and Teva; and remuneration for teaching activities from AcadeMe, Medscape and the Neurology Academy."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported, in part, by Multiple Sclerosis of Great Britain & Northern Ireland grant 69/2017."